Clinical Trials Browser

Interventional × tremelimumab × 30 days × Clear all

NCT02888743 2026-03-18

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04034927 2026-03-18

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Active not recruiting

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT07391670 2026-03-12

IMFINZI-subQ

Phase 1 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Phase 2 Active not recruiting

301 enrolled 15 charts

Lung Cancer Metastatic

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular